Navigation Links
Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc.
Date:5/16/2010

10, and any amendments or supplements thereto. The company's solicitation/recommendation statement will set forth the reasons for the recommendation of the OSI's board and related information. The solicitation/recommendation statement and other public filings made from time to time by OSI with the SEC are available without charge from the SEC's website at www.sec.gov, at OSI's website at www.osip.com or from OSI's information agent, by calling 800-322-2885 toll free or (212) 929-5500 or by emailing osipharma@mackenziepartners.com.  

Statement of Cautionary Factors

This document contains certain forward-looking statements. These forward-looking statements may be identified by words such as 'believes', 'expects', 'anticipates', 'projects', 'intends', 'should', 'seeks', 'estimates', 'future' or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this document, among others: (1) pricing and product initiatives of competitors; (2) legislative and regulatory developments and economic conditions; (3) delay or inability in obtaining regulatory approvals or bringing produc
'/>"/>

SOURCE Astellas Pharma US, Inc.; OSI Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Astellas and Theravance Report Additional Telavancin Data at 47th Annual ICAAC
2. Astellas Pharma US, Inc. and The International Transplant Nurses Society (ITNS) Collaborate on Content for Transplant Experience Program
3. Astellas and Boehringer Ingelheim Reach Settlement Agreement with Ranbaxy on Flomax Patent Case
4. CV Therapeutics and Astellas Announce FDA Approval for Lexiscan(TM) (regadenoson) Injection
5. Astellas Launches Lexiscan(TM) (Regadenoson) Injection for Use as a Pharmacologic Stress Agent in Radionuclide Myocardial Perfusion Imaging (MPI)
6. FDA Approves Astellas Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
7. CV Therapeutics Statement on Unsolicited Proposal From Astellas
8. CV Therapeutics Board of Directors Rejects Astellas Unsolicited Proposal
9. CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas Tender Offer
10. CV Therapeutics Board of Directors Rejects Astellas Tender Offer
11. Astellas Receives FDA Approval for Use of Prograf(R) (Tacrolimus) in Conjunction With Mycophenolate Mofetil (MMF) in Kidney Transplant Recipients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dallas, Texas (PRWEB) December 23, 2014 ... on methyl mercaptan such as its definition, ... also presents product specification, manufacturing process, and ... regions, technology and applications. The analysis also ... survey, marketing channels, industry development trend and ...
(Date:12/24/2014)... 24, 2014 The report expects global ... by 2019. It also provides a carefully analyzed data ... challenges for the market. , Full Copy of Report ... the global market for cell expansion will keep witnessing ... expects this growth to be driven by rapid technological ...
(Date:12/24/2014)... 2014 China Biologic Products, Inc. (NASDAQ: ... fully integrated plasma-based biopharmaceutical company in ... subsidiary, Shandong Taibang Biological Products Co. Ltd., has ... China Food and Drug Administration (the "CFDA") for ... disclosed in the Company,s public filings, the CFDA ...
(Date:12/24/2014)... LONDON , December 23, 2014 ... Review Algeria , out today and available for free ... the actors driving change and growth in the sector today. ... has scored notable successes has been in developing a homegrown ... 70 percent local production still remains some way off. A ...
Breaking Biology Technology:Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3
... , , SEATTLE and ATLANTA, ... it has signed a lease agreement with Majestic Realty Co. to build ... to manufacture PROVENGE(R) (sipuleucel-T) for patients with advanced prostate cancer. The ... , , If approved by the U.S. Food and ...
... , , , , ... results for its first fiscal quarter ended June 30, 2009. Net sales increased 22% ... year. , , Net loss for the quarter was ... of the prior fiscal year of $587,000 or $0.05 per share. The prior ...
... BOZEN, Italy, August 10 , ... Robotics , Health Robotics today announced ... for Health Robotics, CytoCare Robot. The,agreement enables McKesson to achieve ... Oncology I.V. admixtures. , "We are ...
Cached Biology Technology:Dendreon Signs Lease for New Manufacturing Facility in Atlanta 2Dendreon Signs Lease for New Manufacturing Facility in Atlanta 3Imagenetix, Inc. Reports First Quarter 2010 Results 2Imagenetix, Inc. Reports First Quarter 2010 Results 3Imagenetix, Inc. Reports First Quarter 2010 Results 4Imagenetix, Inc. Reports First Quarter 2010 Results 5McKesson Expands Pharmacy Automation Product Portfolio to Include I.V. Therapy 2McKesson Expands Pharmacy Automation Product Portfolio to Include I.V. Therapy 3
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the ... 2015-2019" report to their offering. ... is the adoption of multimodal biometric systems. Multimodal ... an individual for verification and identification purposes. This ...
(Date:12/11/2014)... ST. PAUL, Minn. , Dec. 10, 2014 ... in wireless physiologic monitoring, has released a new ... changing needs of preclinical toxicology researchers. M series, ... to help toxicologists collect the best possible physiologic ... studies. Adding functional endpoints to toxicology ...
(Date:12/10/2014)... 2014  Valencell, a leader in performance biometric data ... demand from its licensees for highly accurate, clinically validated ... solely coming from fitness and health sectors, but first ... wearable is only as useful as the biometric data ... driver in long-term mass consumer adoption of wearable products," ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... Researchers with the UC Davis MIND Institute and Agilent ... disorder best known for causing an insatiable appetite that ... the loss of non-coding RNAs, resulting in the dysregulation ... metabolic differences during sleep. The research was led ...
... YORK, NY (June 25, 2013) Researchers at Columbia ... called caspase-2 is a key regulator of a signaling ... The findings, made in a mouse model of Alzheimer,s, ... damage and subsequent cognitive decline associated with the disease. ...
... added another piece to the evolutionary puzzle to explain why ... remained tiny. In research published in Proceedings of ... including Monash University,s Dr Alistair Evans proposed a new theory ... shrew which weighs around two grams, to the blue whale ...
Cached Biology News:Symptoms of Prader-Willi syndrome associated with interference in circadian, metabolic genes 2Study identifies protein that contributes to cognitive decline in Alzheimer's 2From minute to massive -- mammal size evolution explained 2
... for 1,464 array sample elements. , , ,Includes: ... Blocker BSA in PBS (10X): 50 ml ... Buffered Saline: 8 packs , 10% Tween-20: 2 ... Enhancer: 2 x 25 ml , SuperSignal West Pico ...
... Tecans new HydroFlex platform provides excellent ... range of 96-well format applications, including ... protein arrays, and vacuum filtration-to-waste, such ... outstanding on-line control features set new ...
... gun system, 100-120 V, is used for ... This handheld device employs an adjustable helium ... biomaterial-coated gold microcarriers from the inner wall ... target cells. This system has a 2 ...
... Conjugated peptides, recombinant or native proteins are ... an immunization protocol optimized in time, quantity of ... recommend the use of 2 animals per protocol ... serum yield on a 77-day protocol is approximately ...
Biology Products: